Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first ‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

ConclusionsOur study revealed potential differences in TKI efficacy, resistance mechanism, and prognosis of various EGFR ex19del subtypes in NSCLC, underscoring the need for precise selection of first-line therapy.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research